In early 2015, Janssen Research & Development launched three new research platforms that focus on disease prevention, disease interception and the microbiome – areas of transformational medical innovation that are expected to change the healthcare landscape.

The Disease Interception Accelerator (DIA) is an incubator-like group that addresses the root causes of select diseases. The DIA works to understand disease susceptibility, risk assessment and tackle the origins of disease such as genetic predisposition, environmental exposure and phenotypic alterations. It will utilize a combination of traditional pharmaceutical and other, non-pharmaceutical approaches to intercept disease progression for at-risk populations, thus aiming to promote improved individual and societal health and wellness.